Risk factors for dysbaric osteonecrosis

Rheumatology

Volumn 45, Issue 7, 2006, Pages 855-858

  Miyanishi, Keita ^a   Kamo, Y ^a   Ihara, H ^a   Naka, T ^a   Hirakawa, M ^a   Sugioka, Y ^a  

^a KYUSHU ROSAI HOSPITAL   (Japan)

Author keywords

Coagulation; Dysbaric osteonecrosis; Plasminogen activator inhibitor

Indexed keywords

ANTICOAGULANT AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; AVASCULAR NECROSIS; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; BONE RADIOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DECOMPRESSION SICKNESS; DIVER; DYSBARIC OSTEONECROSIS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DIVING; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OCCUPATIONAL DISEASES; OSTEONECROSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS;

EID: 33745588564     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel013     Document Type: Article

References (26)

1. Medical Research Council Decompression Sickness Central Registry and Radiological Panel. Aseptic bone necrosis in commercial divers. Lancet 1981;2:384-8.
2. Gregg PJ, Walder DN. Caisson disease of bone. Clin Orthop 1986;210:43-54.
3. Kawashima M, Torisu T, Hayashi K, Kitano M. Pathological review of osteonecrosis in divers. Clin Orthop 1978;130:107-17.
4. Catto M. Pathology of aseptic bone necrosis. In: Davidson JK, ed. Aseptic necrosis of bone. Amsterdam: Excerpta Medica, 1976:3-100.
5. Ohta Y, Matsunaga H. Bone lesions in divers. J Bone Joint Surg 1974;56B:3-15.
6. Chryssanthou CP. Dysbaric osteonecrosis. Etiological and pathogenetic concepts. Clin Orthop 1978;130:94-106.
7. Walder DN. Bone necrosis. In: Jardine FM, McCallum RI, eds. Engineering and health in compressed air work. Proceedings of the international conference. Oxford: E & FN Spon, 1994:16-28.
8. Tsugane S, Fahey MT, Sasaki S, Baba S. Alcohol consumption and all-cause and cancer mortality among middle-aged Japanese men: Seven-year follow-up of the JPHC study Cohort I. Japan Public Health Center. Am J Epidemiol 1999;150:1201-7.
9. Ono T, Sogabe M, Ogura M, Furusaki F. Automated latex photometric immunoassay for total plasminogen activator inhibitor-1 in plasma. Clin Chem 2003;49:987-9.
10. The recognition and management of hyperlipidaemia in adults: A policy statement of the European Atherosclerosis Society. Eur Heart J 1988;9:571-600.
11. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-5.
12. Narayan KA, Narayan S, Kummerow FA. Disk electrophoresis of human serum lipoproteins. Nature 1965;205:246-8.
13. Noma A, Hata Y, Goto Y. Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference values, and age- and sex-related differences. Clin Chim Acta 1991;199:147-57.
14. Jones JP, Jr. Fat embolism, intravascular coagulation, and osteonecrosis. Clin Orthop 1993;292:294-308.
15. Glueck CJ, Freiberg RA, Fontaine RN, Tracy T, Wang P. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop 2001; 386:19-33.
16. Miyanishi K, Yamamoto T, Irisa T et al. Bone marrow fat cell enlargement and a rise in intraosseous pressure in steroid-treated rabbits with osteonecrosis. Bone 2002;30:185-90.
17. Yamamoto T, Irisa T, Sugioka Y, Sueishi K. Effects of pulse methylprednisolone on bone and marrow tissues: Corticosteroid-induced osteonecrosis in rabbits. Arthritis Rheum 1997;40:2055-64.
18. Motomura G, Yamamoto T, Miyanishi K, Jingushi S, Iwamoto Y. Combined effects of an anticoagulant and a lipid-lowering agent on the prevention of steroid-induced osteonecrosis in rabbits. Arthritis Rheum 2004;50:3387-91.
19. Glueck CJ, Glueck HI, Mieczkowski L, Tracy T, Speirs J, Stroop D. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis? Thromb Haemost 1993; 69:460-5.
20. Glueck CJ, Fontaine RN, Gruppo R et al. The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop 1999;366:133-46.
21. Jones LC, Mont MA, Le TB et al. Procoagulants and osteonecrosis. J Rheumatol 2003;30:783-91.
22. Miyanishi K, Yamamoto T, Irisa T et al. A high low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a potential risk factor for corticosteroid-induced osteonecrosis in rabbits. Rheumatology 2001;40:196-201.
23. Miyanishi K, Yamamoto T, Irisa T, Noguchi Y, Sugioka Y, Iwamoto Y. Increased level of apolipoprotein B/apolipoprotein A1 ratio as a potential risk for osteonecrosis. Ann Rheum Dis 1999; 58:514-16.
24. Jones JP Jr, Ramirez S, Doty SB. The pathophysiologic role of fat in dysbaric osteonecrosis. Clin Orthop 1993;296:256-64.
25. Jones JP Jr. Intravascular coagulation and osteonecrosis. Clin Orthop 1992;277:41-53.
26. McCallum RI, Walder DN. Bone lesions in compressed air workers, with special reference to men who worked on the Clyde Tunnels 1958 to 1963. Report of Decompression Sickness Panel Medical Research Council. J Bone Joint Surg 1966;48B:207-35.